Hisun Pharmaceutical
Hisun Pharmaceutical, officially known as Zhejiang Hisun Pharmaceutical Co., Ltd., is a prominent player in the global pharmaceutical industry, headquartered in CN. Founded in 1956, the company has established a strong presence in major operational regions, including Asia, Europe, and North America. Hisun Pharmaceutical focuses on the research, development, and manufacturing of a diverse range of products, including generic drugs, active pharmaceutical ingredients (APIs), and innovative therapies. With a commitment to quality and innovation, Hisun has achieved significant milestones, including numerous certifications and partnerships that enhance its market position. The company is recognised for its unique approach to drug development, particularly in oncology and cardiovascular treatments. Hisun Pharmaceutical continues to make strides in the industry, solidifying its reputation as a trusted provider of high-quality pharmaceutical solutions.
DitchCarbon Score
How does Hisun Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hisun Pharmaceutical's score of 22 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hisun Pharmaceutical's reported carbon emissions
Hisun Pharmaceutical, headquartered in China (CN), currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges, indicating a lack of formal commitments to address carbon emissions at this time. The absence of emissions data and reduction initiatives suggests that Hisun Pharmaceutical may be in the early stages of developing a comprehensive climate strategy. In the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and are setting ambitious targets to reduce their carbon footprints. However, without specific commitments or data, it is unclear how Hisun Pharmaceutical plans to align with these industry trends. As the company moves forward, it may benefit from adopting industry-standard climate initiatives, such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP), to enhance its climate commitments and transparency.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hisun Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
